



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

		Application Number	10/712,425
		Filing Date	November 13, 2003
		First Named Inventor	Lee
		Art Unit	1631
		Examiner Name	Lin, Jerry
Total Number of Pages in This Submission		Attorney Docket Number	EPT-001C1

**ENCLOSURES (Check all that apply)**

<input checked="" type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input checked="" type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): <ul style="list-style-type: none"> <li>- PTO Form SB/08a/b citing references A6-A31, B4-B11, and C14-C55</li> <li>- Certificate of First Class Mailing</li> <li>- Return Receipt Postcard</li> </ul>
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	
<input checked="" type="checkbox"/> Supplemental Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts/ Incomplete Application	<b>Remarks</b>	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm Name	GOODWIN PROCTER LLP		
Signature			
Printed name	Randall D. Morin		
Date	October 3, 2006	Reg. No.	58,312

Under the Paperwork Reduction Act of 1995, no person are required to respond to a collection of information unless it displays a valid OMB control number.

Effective on 12/08/2004.

Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).

# FEE TRANSMITTAL For FY 2005

Applicant claims small entity status. See 37 CFR 1.27

<b>TOTAL AMOUNT OF PAYMENT</b>	(\$)	180.00
--------------------------------	------	--------

		<b>Complete if Known</b>
--	--	--------------------------

Application Number	10/712,425
Filing Date	November 13, 2003
First Named Inventor	Lee
Examiner Name	Lin, Jerry
Art Unit	1631
Attorney Docket No.	EPT-001C1

## METHOD OF PAYMENT (check all that apply)

Check    Credit Card    Money Order    None    Other (please identify): \_\_\_\_\_

Deposit Account   Deposit Account Number: 07-1700   Deposit Account Name: \_\_\_\_\_ Goodwin Procter LLP

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

Charge fee(s) indicated below    Charge fee(s) indicated below, except for the filing fee  
 Charge any additional fee(s) or underpayment of    Credit any overpayments  
fee(s) under 37 CFR 1.16 and 1.17

## FEE CALCULATION

### 1. BASIC FILING, SEARCH, AND EXAMINATION FEES

<u>Application Type</u>	<u>FILING FEES</u>		<u>SEARCH FEES</u>		<u>EXAMINATION FEES</u>		<u>Fees Paid (\$)</u>
	<u>Fee (\$)</u>	<u>Small Entity Fee (\$)</u>	<u>Fee (\$)</u>	<u>Small Entity Fee (\$)</u>	<u>Fee (\$)</u>	<u>Small Entity Fee (\$)</u>	
Utility	300	150	500	250	200	100	
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	

### 2. EXCESS CLAIM FEES

#### Fee Description

Each claim over 20 (including Reissues)

<u>Small Entity</u>	
<u>Fee (\$)</u>	<u>Fee (\$)</u>

50      25

Each independent claim over 3 (including Reissues)

200      100

Multiple dependent claims

360      180

<u>Total Claims</u>	<u>Extra Claims</u>	<u>Fee (\$)</u>	<u>Fee Paid (\$)</u>	<u>Multiple Dependent Claims</u>	
- 20 =	x	=	0.00	<u>Fee (\$)</u>	<u>Fee Paid (\$)</u>

HP = highest number of total claims paid for, if greater than 20.

0.00

<u>Indep. Claims</u>	<u>Extra Claims</u>	<u>Fee (\$)</u>	<u>Fee Paid (\$)</u>	<u>Multiple Dependent Claims</u>	
- 3 =	x	=	0.00	<u>Fee (\$)</u>	<u>Fee Paid (\$)</u>

HP = highest number of independent claims paid for, if greater than 3.

0.00

### 3. APPLICATION SIZE FEE

If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

<u>Total Sheets</u>	<u>Extra Sheets</u>	<u>Number of each additional 50 or fraction thereof</u>	<u>Fee (\$)</u>	<u>Fee Paid (\$)</u>
- 100 =	/50	(round up to a whole number) x	=	0.00


### 4. OTHER FEE(S)

Non-English Specification, \$130 fee (no small entity discount)

Other (e.g., late filing surcharge): Submission of a Supplemental Information Disclosure Statement

180.00

#### SUBMITTED BY

Signature		Registration No. (Attorney/Agent)	58,312	Telephone	(617) 570-1000
Name (Print/Type)	Randall D. Morin	Date	October 3, 2006		



JFC/SB

**PATENT**  
Attorney Docket No. EPT-001C1

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): *Lee et al.*

SERIAL NO.: 10/712,425 GROUP NO.: 1631

FILING DATE: November 13, 2003 EXAMINER: Lin, Jerry

TITLE: PROTEOME EPITOPE TAGS AND METHODS OF USE  
THEREOF IN PROTEIN MODIFICATION ANALYSIS

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

### SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicants hereby make of record the patents and publications listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. In accordance with 37 C.F.R. 1.98(a)(2), only copies of the foreign patent documents and non-patent publications are enclosed.

In addition, Applicants wish to inform the Examiner about the following U.S. patent applications and the contents of their file wrappers, including all Office actions issued therein:

1. U.S.S.N. 10/436,549, entitled "Unique Recognition Sequences and Methods of Use Thereof in Protein Analysis," filed on May 12, 2003, and published as 2004/0038307 A1, on February 26, 2005 (A28 in attached form PTO/SB/08a/b).
2. U.S.S.N. 10/773,032, entitled "Proteome Epitope Tags and Methods of Use Thereof in Protein Modification Analysis," filed on February 5, 2004, and published as 2005/0069911 A1, on March 31, 2005 (A29 in attached form PTO/SB/08a/b).
3. U.S.S.N. 11/066,967, entitled "Proteome Epitope Tags and Methods of Use Thereof in Protein Modification Analysis," filed on February 5, 2005, and published as 2006/0014212 A1, on January 19, 2006 (A30 in attached form PTO/SB/08a/b).

10/10/2006 RMBRAHT 00000075 10712425

01 FC:1806

180.00 0P

Supplemental Information Disclosure Statement

Serial No. 10/712,425

Page 2 of 2

4. U.S.S.N. 11/249,847, entitled "Unique Recognition Sequences and Methods of Use Thereof in Protein Analysis," filed on October 13, 2005, and published as 2006/0035270 A1 on February 16, 2006 (A31 in attached form PTO/SB/08a/b).

**REMARKS**

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed (CHECK ONE):

- (1) within three (3) months of the **filing date** of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the **date of entry of the national stage** as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the **first Office action** on the merits, or before the mailing of a **first Office action** after the filing of a request for continued examination under 37 C.F.R. 1.114; or
- (2) after the period defined in (1) but before the mailing date of a **final action** or a **notice of allowance** under 37 C.F.R. 1.311, and
- the requisite Statement is below, **OR**
- the requisite fee under 37 C.F.R. 1.17(p), namely **\$180.00**, is included herein, or
- (3) after the mailing date of a **final action** or **notice of allowance** but before the payment of the **issue fee**, **AND**
- the requisite Statement is below, **AND**
- the requisite petition fee under 37 C.F.R. 1.17(p), namely **\$180.00** is included herein.

It is respectfully requested that each of the patents and publications listed on the attached Form PTO-1449, and other information contained herein, be made of record in this application.

Respectfully submitted,



Randall D. Morin  
Attorney for Applicants  
Goodwin Procter LLP  
Exchange Place  
Boston, Massachusetts 02109  
Customer No. 051414

Date: October 3, 2006  
Reg. No.: 58,312

Tel. No.: (617) 570-1657  
Fax No.: (617) 523-1231  
VER 11/03  
2851178



PTO/SB/08a/b (07-06)

Approved for use through 09/30/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
				Application Number	10/712,425
				Filing Date	November 13, 2003
				First Named Inventor	Lee
				Art Unit	1631
				Examiner Name	Lin, Jerry
Sheet	1	of	3	Attorney Docket Number	EPT-001C1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
A6		4,478,744	10/23/1984	Mezei <i>et al.</i>	
A7		6,113,897	9/5/2000	Dano <i>et al.</i>	
A8		6,225,047	5/1/2001	Hutchens	
A9		2004/0229284	11/18/2004	Luciw <i>et al.</i>	
A10		2005/0214304	9/29/2005	Pastan <i>et al.</i>	
A11		5,955,317	9/21/1999	Suzuki <i>et al.</i>	
A12		2003/0054408 A1	3/20/2003	Ravi <i>et al.</i>	
A13		5,708,155	1/13/1998	Potter <i>et al.</i>	
A14		5,763,158	6/9/1998	Bohannon <i>et al.</i>	
A15		5,790,155	8/4/1998	Usui <i>et al.</i>	
A16		5,798,155	8/25/1998	Yanagawa <i>et al.</i>	
A17		5,872,234	2/16/1999	Bandman <i>et al.</i>	
A18		5,961,923	10/5/1999	Nova <i>et al.</i>	
A19		6,261,569	7/17/2001	Comis <i>et al.</i>	
A20		6,420,125	7/16/2002	Fleddelius <i>et al.</i>	
A21		2002/0042386 A1	4/11/2002	Rosen <i>et al.</i>	
A22		2002/0055186 A1	5/9/2002	Barry <i>et al.</i>	
A23		2002/0081617 A1	6/27/2002	Buranda <i>et al.</i>	
A24		2002/0110843 A1	8/15/2002	Dumas	
A25		2003/0028330 A1	2/6/2003	Cheng <i>et al.</i>	
A26		2003/0032039 A1	9/12/2002	Cunningham <i>et al.</i>	
A27		2003/0044862 A1	3/6/2003	Giaccia <i>et al.</i>	
A28		2004/0038307 A1	02/26/2004	Lee <i>et al.</i>	
A29		2005/0069911 A1	03/31/2005	Lee <i>et al.</i>	
A30		2006/0014212 A1	01/19/2006	Benkovic <i>et al.</i>	
A31		2006/0035270 A1	02/16/2006	Lee <i>et al.</i>	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)			
B4		DE 40 23 945	1/30/1992		(trans. abstract only) X
B5		EP 0 337 057	1/23/1989		(trans. abstract only) X
B6		EP 0 267 355	3/27/1987		(trans. abstract only) X
B7		WO 05/50223	6/2/2005	Epitome Biosystems, Inc.	
B8		WO 05/78453	8/25/2005	Epitome Biosystems, Inc.	
B9		JP 07-285999 A	10/31/1995	Prima Meat Packers Ltd.	X
B10		WO 02/06834 A	1/24/2002	Pointilliste, Inc.	
B11		WO 99/39210 A	8/5/1999	Miller	

Examiner Signature	Date Considered
--------------------	-----------------

Substitute for form 1449A/B/PTO				<b>Complete if Known</b>	
				Application Number	10/712,425
				Filing Date	November 13, 2003
				First Named Inventor	Lee
				Art Unit	1631
				Examiner Name	Lin, Jerry
Sheet	2	of	3	Attorney Docket Number	EPT-001C1

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

<b>NON PATENT LITERATURE DOCUMENTS</b>			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C14	Armheiter <i>et al.</i> (1981) "Physiochemical and Antigenic Properties of Synthetic Fragments of Human Leukocyte Interferon," <i>Nature</i> 294: 278-80.	
	C15	Arnon (1991) "Synthetic Peptides as the Basis for Vaccine Design," <i>Molecular Immunology</i> 28(3) 209-215.	
	C16	Barbas III <i>et al.</i> (1991) "Assembly of Combinatorial Antibody Libraries on Phage Surfaces: The Gene III Site," <i>PNAS USA</i> 88: 7978-7982.	
	C17	Barry <i>et al.</i> (2003) "Competitive Assay Formats for High-Throughput Affinity Arrays," <i>J. Biomol. Screen.</i> *(3): 257-263.	
	C18	Borreback (2000) "Antibodies in Diagnostics - From Immunoassays to Protein Chips," <i>Immunology Today</i> 21(8): 379-381.	
	C19	Chames <i>et al.</i> (2000) "Antibody Engineering and its Applications in Tumor Targeting in Intracellular Immunization," <i>FEMS Microbiology Letters</i> 189: 1-8.	
	C20	Chou <i>et al.</i> (1974) "Prediction of Protein Conformation," <i>Biochemistry</i> 13(2): 222-245.	
	C21	Devereux <i>et al.</i> (1984) "A Comprehensive Set of Sequence Analysis Programs for the VAX," <i>Nucleic Acids Research</i> 12 (1) 387-395.	
	C22	Erali <i>et al.</i> (1996) "ELISA for Thyroglobulin in Serum: Recovery Studies to Evaluate Autoantibody Interference and Reliability of Thyroglobulin Values," <i>Clinical Chemistry</i> 42: 766-770.	
	C23	European Supplementary Search Report for EPSN 03808371, completed 06/01/2006, dated 06/12/2006 (7 pages).	
	C24	Harper <i>et al.</i> (1998) Two-Dimensional Gel Electrophoresis, Unit 10.4, Current Protocols in Protein Science, pgs. 10.4.1 to 10.4.36.	
	C25	Haupt <i>et al.</i> (1998) "Plastic Antibodies: Developments and Applications," <i>Trends Biotech.</i> 16: 468-475.	
	C26	Hellmold <i>et al.</i> (2002) "Identification of End Points Relevant to Detection of Potentially Adverse Drug Reactions," <i>Toxicology Letters</i> 127: 239-243.	
	C27	Hemminki <i>et al.</i> (1998) "Fine Tuning of an Anti-Testosterone Antibody Binding Site by Stepwise Optimisation of the CDRs," <i>Immunotechnology</i> 4: 59-69.	
	C28	Hennig (1998) "WinPep-ein Programm zur Analyse von Aminosäuresequenzen," <i>Biospektrum</i> 4(5): 49-50.	
	C29	Hoogenboom <i>et al.</i> (1998) "Antibody Phage Display Technology and its Applications," <i>Immunotechnology</i> 4: 1-20.	
	C30	Hoogenboom <i>et al.</i> (2000) "Natural and Designer Binding Sites Made by Phage Display Technology," <i>Immunology Today</i> 21(8): 371-378.	
	C31	Hopp <i>et al.</i> (1983) "A Computer Program For Predicting Protein Antigenic Determinants," <i>Molecular Immunology</i> 20(4): 483-489.	
	C32	International Search Report for PCT/US2003/014846, mailed on 11/30/2004 (2 pages).	
	C33	International Search Report for PCT/US2004/038283, mailed on 12/22/2005 (6 pages).	
	C34	International Search Report for PCT/US2005/003634, mailed on 09/15/2005 (3 pages).	
	C35	Kuruvilla <i>et al.</i> (2002) "Dissecting Glucose Signaling with Diversity-Oriented Synthesis and Small-Molecule Microarrays," <i>Nature</i> 416: 653-657.	
	C36	Kyte <i>et al.</i> (1982) "A Simple Method for Displaying the Hydropathic Character of a Protein," <i>J. Mol. Biol.</i> 157: 105-132.	
	C37	Lesko <i>et al.</i> (2001) "Use of Biomarkers and Surrogate Endpoints in Drug Development and Regulatory Decision Making: Criteria, Validation, Strategies," <i>Annu. Rev. Pharmacol. Toxicol.</i> 41: 347-366.	
	C38	Li (2000) "Applications of Display Technology in Protein Analysis," <i>Nature Biotechnology</i> 18: 1251-1256.	
	C39	Lizardi <i>et al.</i> (1998) "Mutation Detection and Single Molecule Counting Using Isothermal Rolling Circle Amplification," <i>Mat. Genet.</i> 19: 225-232.	
	C40	Maggio (1980) Enzyme-immunoassay, pgs. 53-70.	

Examiner Signature	Date Considered
--------------------	-----------------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				<i>Complete if Known</i>	
				Application Number	10/712,425
				Filing Date	November 13, 2003
				First Named Inventor	Lee
				Art Unit	1631
				Examiner Name	Lin, Jerry
Sheet	3	of	3	Attorney Docket Number	EPT-001C1


C41	Mariani <i>et al.</i> (1987) "Immunogenicity of a Free Synthetic Peptide: Carrier Conjugation Enhances Antibody Affinity for the Native Protein," <i>Molecular Immunology</i> 24(3): 297-303.	
C42	Marks <i>et al.</i> (1992) "By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling," <i>Bio/Technology</i> 10: 779-783.	
C43	Michaud <i>et al.</i> (2003) "Analyzing Antibody Specificity with Whole Proteome Microarrays," <i>Nat. Biotech.</i> 21(12) 1509-12 (e-publication 11/9/03).	
C44	Nelson <i>et al.</i> (2000) "Demystified...Monoclonal Antibodies," <i>J. Clin. Pathol.: Mol. Pathol.</i> 53: 111-117.	
C45	Ohlin <i>et al.</i> (1996) "Light Chain Shuffling of a High Affinity Antibody Results in a Drift in Epitope Recognition," <i>Molecular Immunology</i> 33(1): 47-56.	
C46	Rosenkranz (2003) "Biomarkers and Surrogate Endpoints in Clinical Drug Development," <i>Applied Clinical Trials</i> , pgs. 30-34, 40.	
C47	Schweitzer <i>et al.</i> (2002) "Multiplexed Protein Profiling on Microarrays by Rolling-Circle Amplification," <i>Nat. Biotechnol.</i> 20: 359-365.	
C48	Scrivener <i>et al.</i> (2003) "Peptidomics: A New Approach to Affinity Protein Microarrays," <i>Proteomics</i> 3: 122-128.	
C49	Shea <i>et al.</i> (1993) "Immunologic Detection and Measurement of Glycated Apolipoprotein B with Site Specific Monoclonal Antibodies," <i>J. Immunol. Methods</i> 162(1): 85-95.	
C50	Soderlind <i>et al.</i> (1999) "Complementary-Determining Region (CDR) Implantation: A Theme of Recombination," <i>Immunotechnology</i> 4: 279-285.	
C51	Soderlind <i>et al.</i> (2000) "Recombinant Germline-Derived CDR Sequences for Creating Diverse Single-Framework Antibody Libraries," <i>Nature Biotechnology</i> 18: 852-856.	
C52	Soloviev <i>et al.</i> (2003) "Combinatorial Peptidomics: A Generic Approach for Protein Expression Profiling," <i>J. of Nanobiotechnology</i> 1: 1-19.	
C53	Vlatakis <i>et al.</i> (1993) "Drug Assay Using Antibody Mimics Made by Molecular Imprinting," <i>Nature</i> 361: 645-647.	
C54	Weckwerth (2003) "Metabolomics in Systems Biology," <i>Annu. Rev. Plant Biol.</i> 54: 669-689.	
C55	Werkmeister <i>et al.</i> (1991) "Multiple Antigenic Determinants on Type III Collagen," <i>Biochem. J.</i> 274: 895-898.	

LIBC/2851039.1

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Date Considered
--------------------	-----------------



PTO/SB/92 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application No. (if known): 10/712,425

Attorney Docket No.: EPT-001C1

## Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on October 3, 2006  
Date

Signature

Randall D. Morin

Typed or printed name of person signing Certificate

58,312

Registration Number, if applicable

(617) 570-1000

Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

- Transmittal Form (1 page)
- Fee Transmittal (1page)
- Supplemental Information Disclosure Statement (2 pages)
- PTO Form SB/08a/b citing references A6-A31, B4-B11, and C14-C55 (3 pages)
- Copies of cited references B4-B11 and C14-C54
- Check in the amount of \$180.00
- Return Receipt Postcard

2851186